Aethyl-<2-propoxy-aethyl>-amin | 58203-08-0

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: Aethyl-<2-propoxy-aethyl>-amin
• 英文别名: N-ethyl-2-propoxyethanamine
• CAS: 58203-08-0
• 化学式: C₇H₁₇NO
• 分子量: 131.218
• InChiKey: XZSUQWJCQKJQDQ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.9
• 重原子数：
  9
• 可旋转键数：
  6
• 环数：
  0.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  21.3
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  Aethyl-<2-propoxy-aethyl>-amin 以80%的产率得到
  参考文献：
  名称：

  BANKS R.; BROOKES R. F.; GODSON D. H., J. CHEM. SOC. PERKIN TRANS. PART 1 , 1975, NO 19, 1836-1840

  摘要：

  DOI：
• 作为产物：
  描述：

  2-溴乙基正丙基醚 、 乙胺 在 sodium hydroxide 作用下， 生成 Aethyl-<2-propoxy-aethyl>-amin
  参考文献：
  名称：

  Banks,R. et al., Journal of the Chemical Society. Perkin transactions I, 1975, p. 1836 - 1840

  摘要：

  DOI：

文献信息

• BIARYL AMIDE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF
  申请人：Katayama Seiji

  公开号：US20130116227A1

  公开（公告）日：2013-05-09

  Disclosed is a novel biaryl amide derivative represented by formula (1) and having an affinity for the aldosterone receptor; also disclosed is a pharmaceutically acceptable salt thereof. (In the formula, A is any of the groups represented by formula (a); L is —CONH—, etc.; R 1 is a substitutable aminosulfonyl group, etc.; R 2 is a hydrogen atom, etc.; R 3 is a hydrogen atom, etc.; R 4 is a hydrogen atom, a halogen atom, hydroxy group, a substitutable amino group, a substitutable C 1-6 alkoxy group, a substitutable 4- to 7-membered cyclic amino group, etc.; R 5a , R 5b and R 5c are each independently hydrogen atoms, etc.; R 6 is a halogen atom, a cyano group, etc.; R 7 and R 8 are each independently a hydrogen atom, etc.; and m is an integer such as 0.)

  揭示了一种表示为公式（1）的新型联苯酰胺衍生物，具有与醛固酮受体的亲和力；还揭示了其药用可接受的盐。（在该公式中，A是由公式（a）表示的任何基团之一；L是—CONH—等；R1是可替代的氨基磺酰基等；R2是氢原子等；R3是氢原子等；R4是氢原子、卤原子、羟基、可替代的氨基基团、可替代的C1-6烷氧基、可替代的4-到7-成员环氨基基团等；R5a、R5b和R5c各自独立地是氢原子等；R6是卤原子、氰基等；R7和R8各自独立地是氢原子等；m是整数，例如0。）
• QUINAZOLINE DERIVATIVE AS TYROSINE-KINASE INHIBITOR, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF
  申请人：Wu Frank

  公开号：US20140161801A1

  公开（公告）日：2014-06-12

  The invention relates to a quinazoline derivative represented by the general formula (I), a pharmaceutical acceptable salt and a stereoisomer thereof as tyrosine kinase inhibitor, wherein R 1 , R 2 , R 3 , R 3′ , R 4 , R 5 , R 6 , X, L, T, Z and q are as defined in the specification. The invention also relates to a process for preparing the same, a pharmaceutical composition and a pharmaceutical formulation containing the derivative, use of the derivative for treating excessive proliferative diseases and chronic obstructive pulmonary disease and use of the derivative in the manufacture of a medicament for treating excessive proliferative diseases and chronic obstructive pulmonary disease.

  该发明涉及一种喹唑啉衍生物，其通式表示为(I)，作为酪氨酸激酶抑制剂的药用可接受盐和立体异构体，其中R1、R2、R3、R3'、R4、R5、R6、X、L、T、Z和q如规范中所定义。该发明还涉及一种制备该衍生物的方法，包含该衍生物的药用组合物和药用配方，以及将该衍生物用于治疗过度增殖性疾病和慢性阻塞性肺病，以及将该衍生物用于制造用于治疗过度增殖性疾病和慢性阻塞性肺病的药物。
• CONJUGATED MICROPOROUS MACROMOLECULE CATALYST COMPLEXED WITH COBALT, CHROMIUM, ZINC, COPPER OR ALUMINIUM, PREPARATION AND USE THEREOF
  申请人：DALIAN INSTITUTE OF CHEMICAL PHYSICS, CHINESE ACADEMY OF SCIENCES

  公开号：US20140066533A1

  公开（公告）日：2014-03-06

  Disclosed are a type of catalyst which can catalyse the ring-addition reaction of CO 2 and an alkylene oxide at 0˜180° C. under 0.1˜8.0 MPa to produce a corresponding cyclic carbonate, and the preparation thereof. The catalyst is a conjugated microporous macromolecule polymer complexed with cobalt, chromium, zinc, copper or aluminium, and by using the macromolecule catalysts complexed with different metals to catalyse the reaction of CO 2 and alkylene oxide at normal temperature and normal pressure, a yield of the corresponding cyclic carbonate of 35%˜90% can be obtained. The catalyst is easy to recover and the re-use of the catalyst has no influence on the yield; additionally, the yield can reach over 90% by controlling the reaction conditions.

  本文披露了一种催化剂，可以在0~180°C、0.1~8.0 MPa的条件下催化CO2和烯丙基氧化物的环加成反应，生成相应的环状碳酸酯，以及其制备方法。该催化剂是与钴、铬、锌、铜或铝络合的共轭微孔大分子聚合物，通过使用络合不同金属的大分子催化剂在常温常压下催化CO2和烯丙基氧化物的反应，可以获得35%~90%的相应环状碳酸酯产率。该催化剂易于回收，催化剂的再利用对产率没有影响；此外，通过控制反应条件，产率可以达到90%以上。
• 5-Substituted 1-Phenyl-1,5-Dihydro-Pyrido[3,2-B]Indol-2-Ones and Analogs as Anti-Virals
  申请人：Kesteleyn Rudolf Romanie Bart

  公开号：US20070238727A1

  公开（公告）日：2007-10-11

  Compounds of formula (I) the N-oxides, salts, stereoisomeric forms, prodrugs, esters and metabolites thereof, wherein X is NR 2 , O, S, SO, SO 2 ; R 1 is hydrogen, cyano, halo, a carbonyl derivative, methanimidamidyl, N-hydroxy-methanimidamidyl, mono- or di(C 1-4 alkyl)-methanimidamidyl, Het 1 or Het 2 ; n is 1, 2 or 3; R 2 is (i) aryl substituted with a radical —COOR 4 ; (ii) C 1-10 alkyl, C 2-10 alkenyl, C 3-7 cycloalkyl, substituted with aryl which is substituted with a radical —COOR 4 ; (iii) C 1-10 alkyl, C 2-10 alkenyl, C 3-7 cycloalkyl, substituted with —NR 5a —C(═NR 5b )—NR 5c R 5d , —O—NR 5a —C(═NR 5b )—NR 5c R 5d , -sulfonyl-R 6 , —NR 7 R 8 , —NR 9 R 10 , a radical (a-1), (a-2), (a-3), (a-4), (a-5); or (iv) a radical of formula: (a-6), (b-2), —C p H 2p —CH(OR 14 )—C q H 2q —R 15 ; —CH 2 —CH 2 —(O—CH 2 —CH 2 ) m —OR 14 ; —CH 2 —CH 2 —(O—CH 2 —CH2) m —NR 17a R 17b ; R 3 is nitro, cyano, amino, halo, hydroxy, C 1-4 alkyloxy, a carbonyl derivative, methanimidamidyl, mono- or di(C 1-4 alkyl)methanimidamidyl, N-hydroxy-methanimidamidyl or Het 1 .

  化合物的公式（I），包括其N-氧化物、盐、立体异构体形式、前药、酯和代谢物，其中X是NR2、O、S、SO、SO2；R1是氢、氰、卤素、一个羰基衍生物、甲酰亚胺基、N-羟甲酰亚胺基、单个或双个（C1-4烷基）-甲酰亚胺基、Het1或Het2；n为1、2或3；R2是（i）芳基，其被基团—COOR4取代；（ii）C1-10烷基、C2-10烯基、C3-7环烷基，被芳基取代，该芳基被基团—COOR4取代；（iii）C1-10烷基、C2-10烯基、C3-7环烷基，被—NR5a—C（═NR5b）—NR5cR5d、—O—NR5a—C（═NR5b）—NR5cR5d、-磺酰基-R6、—NR7R8、—NR9R10、一个基团（a-1）、（a-2）、（a-3）、（a-4）、（a-5）取代；或（iv）公式的基团：（a-6）、（b-2）、—CpH2p—CH（OR14）—CqH2q—R15；—CH2—CH2—（O—CH2—CH2）m—OR14；—CH2—CH2—（O—CH2—CH2）m—NR17aR17b；R3是硝基、氰基、氨基、卤素、羟基、C1-4烷氧基、一个羰基衍生物、甲酰亚胺基、单个或双个（C1-4烷基）甲酰亚胺基、N-羟甲酰亚胺基或Het1。
• COUPLING OF POLYPEPTIDES AT THE C-TERMINUS
  申请人：NOVO NORDISK HEALTH CARE AG

  公开号：US20140045753A1

  公开（公告）日：2014-02-13

  The present invention relates to novel polypeptides, methods for their synthesis, pharmaceutical compositions comprising the novel polypeptides as well as their use in medicaments for therapeutic applications.

  本发明涉及新型多肽，其合成方法，包含这些新型多肽的药物组合物，以及它们在治疗应用的药物中的使用。